Back to portfolio


Inversago Pharma is a specialty biotechnology company developing new generations of peripherally-restricted cannabinoid type 1 (CB1) receptor inverse agonists/antagonists for the treatment of Prader-Willi syndrome (PWS), type 1 diabetes (T1DM), obesity and other metabolic disorders, such as non-alcoholic fatty liver (NASH). Inversago has the technology to overcome the limitations associated with first-generation CB1 inhibitors and exploit their full medical potential.


Sector of activity

  • Health